Rebastinib is a small molecule inhibitor primarily known for its role in targeting specific kinases involved in cancer cell signaling pathways. It is particularly noted for its activity against the ABL and SRC family of kinases, which are implicated in various malignancies, including chronic myeloid leukemia and solid tumors. The compound is characterized by its ability to disrupt the phosphorylation processes that drive tumor growth and survival, making it a candidate for therapeutic applications in oncology. Rebastinib has been studied in clinical trials, showcasing its potential to inhibit tumor progression and improve patient outcomes. Its chemical structure includes specific functional groups that contribute to its binding affinity and selectivity for its targets. As with many investigational drugs, ongoing research is focused on optimizing its efficacy, understanding its pharmacokinetics, and evaluating its safety profile in diverse patient populations. Overall, Rebastinib represents a promising avenue in targeted cancer therapy, reflecting the broader trend of developing precision medicines in oncology.

Rebastinib

1020172-07-9: N-[3-tert-Butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl]-N'-[2-fluoro-4-[(2-(methylcarbamoyl)pyridin-4-yl)oxy]phenyl]urea, Dcc-2036

DCC-2036 (Rebastinib (DCC-2036)) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC,

4-(4-(3-(3-(Tert-Butyl)-1-(Quinolin-6-Yl)-1H-Pyrazol-5-Yl)Ureido)-3-Fluorophenoxy)-N-Methylpicolinamide

Inhibits multiple tyrosine kinases (Abl1, Src family kinases, Tie-2 and VEGFR-2)

CAS 1020172-07-9: Rebastinib

Rebastinib

Ref: TM-T2640

4-(4-(3-(3-(Tert-Butyl)-1-(Quinolin-6-Yl)-1H-Pyrazol-5-Yl)Ureido)-3-Fluorophenoxy)-N-Methylpicolinamide

Ref: 54-PC108457

DCC 2036

Ref: 3D-FD64998

Rebastinib

Ref: 54-BUP10073

2-Pyridinecarboxamide, 4-[4-[[[[3-(1,1-dimethylethyl)-1-(6-quinolinyl)-1H-pyrazol-5-yl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-

Ref: IN-DA0006BU